43 related articles for article (PubMed ID: 20094661)
1. Toward synthesis of third-generation spin-labeled podophyllotoxin derivatives using isocyanide multicomponent reactions.
Kou L; Wang MJ; Wang LT; Zhao XB; Nan X; Yang L; Liu YQ; Morris-Natschke SL; Lee KH
Eur J Med Chem; 2014 Mar; 75():282-8. PubMed ID: 24553146
[TBL] [Abstract][Full Text] [Related]
2. Podophyllic Aldehyde, a Podophyllotoxin Derivate, Elicits Different Cell Cycle Profiles Depending on the Tumor Cell Line: A Systematic Proteomic Analysis.
Hernández ÁP; Chaparro-González L; Garzo-Sánchez O; Arias-Hidalgo C; Juanes-Velasco P; García PA; Castro MÁ; Fuentes M
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731850
[TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis, and Biological Evaluation of Novel Biotinylated Podophyllotoxin Derivatives as Potential Antitumor Agents.
Zi CT; Gao YS; Yang L; Feng SY; Huang Y; Sun L; Jin Y; Xu FQ; Dong FW; Li Y; Ding ZT; Zhou J; Jiang ZH; Yuan ST; Hu JM
Front Chem; 2019; 7():434. PubMed ID: 31281809
[TBL] [Abstract][Full Text] [Related]
4. Six enzymes from mayapple that complete the biosynthetic pathway to the etoposide aglycone.
Lau W; Sattely ES
Science; 2015 Sep; 349(6253):1224-8. PubMed ID: 26359402
[TBL] [Abstract][Full Text] [Related]
5. Chemistry and Biological Activities of Naturally Occurring and Structurally Modified Podophyllotoxins.
Jin L; Song Z; Cai F; Ruan L; Jiang R
Molecules; 2022 Dec; 28(1):. PubMed ID: 36615496
[TBL] [Abstract][Full Text] [Related]
6. Insight Into the Molecular Mechanism of Podophyllotoxin Derivatives as Anticancer Drugs.
Fan HY; Zhu ZL; Xian HC; Wang HF; Chen BJ; Tang YJ; Tang YL; Liang XH
Front Cell Dev Biol; 2021; 9():709075. PubMed ID: 34447752
[TBL] [Abstract][Full Text] [Related]
7. Podophyllotoxin: History, Recent Advances and Future Prospects.
Shah Z; Gohar UF; Jamshed I; Mushtaq A; Mukhtar H; Zia-Ui-Haq M; Toma SI; Manea R; Moga M; Popovici B
Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33921719
[TBL] [Abstract][Full Text] [Related]
8. Novel tandem biotransformation process for the biosynthesis of a novel compound, 4-(2,3,5,6-tetramethylpyrazine-1)-4'-demethylepipodophyllotoxin.
Tang YJ; Zhao W; Li HM
Appl Environ Microbiol; 2011 May; 77(9):3023-34. PubMed ID: 21398491
[TBL] [Abstract][Full Text] [Related]
9. DNA topoisomerase II poisons and inhibitors.
Capranico G; Giaccone G; Zunino F; Garattini S; D'Incalci M
Cancer Chemother Biol Response Modif; 1997; 17():114-31. PubMed ID: 9551211
[No Abstract] [Full Text] [Related]
10. Recent developments towards podophyllotoxin congeners as potential apoptosis inducers.
Kamal A; Hussaini SM; Malik MS
Anticancer Agents Med Chem; 2015; 15(5):565-74. PubMed ID: 25469512
[TBL] [Abstract][Full Text] [Related]
11. Novel 4 beta-anilino-podophyllotoxin derivatives: design synthesis and biological evaluation as potent DNA-topoisomerase II poisons and anti-MDR agents.
Hu C; Xu D; Du W; Qian S; Wang L; Lou J; He Q; Yang B; Hu Y
Mol Biosyst; 2010 Feb; 6(2):410-20. PubMed ID: 20094661
[TBL] [Abstract][Full Text] [Related]
12. Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines.
Rothenborg-Jensen L; Hansen HF; Wessel I; Nitiss JL; Schmidt G; Jensen PB; Sehested M; Jensen LH
Anticancer Drug Des; 2001 Dec; 16(6):305-15. PubMed ID: 12375883
[TBL] [Abstract][Full Text] [Related]
13. Antitumor agents. 194. Synthesis and biological evaluations of 4-beta-mono-, -di-, and -trisubstituted aniline-4'-O-demethyl-podophyllotoxin and related compounds with improved pharmacological profiles.
Zhu XK; Guan J; Tachibana Y; Bastow KF; Cho SJ; Cheng HH; Cheng YC; Gurwith M; Lee KH
J Med Chem; 1999 Jul; 42(13):2441-6. PubMed ID: 10395485
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of new 4beta-anilino- and 4beta-imido-substituted podophyllotoxin congeners.
Kamal A; Gayatri NL; Reddy DR; Mohan Reddy PS; Arifuddin M; Dastidar SG; Kondapi AK; Rajkumar M
Bioorg Med Chem; 2005 Nov; 13(22):6218-25. PubMed ID: 16061385
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
